NCT06690827View on ClinicalTrials.gov

Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 13, 2024

Primary Completion Date

October 30, 2027

Study Completion Date

October 30, 2028

Conditions
AML (Acute Myeloid Leukemia)BPDCN (blastic Plasmacytoid Dendritic Cell Neoplasm)
Interventions
DRUG

Anti-CD123 CAR NK cells

Each patient will receive two CAR-NK cell infusions at D0 and D7, and CAR-NK cells need to be controlled within 70 minutes from thawing to infusion completion.

Trial Locations (1)

430030

RECRUITING

Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology., Wuhan

All Listed Sponsors
lead

Chongqing Precision Biotech Co., Ltd

INDUSTRY